Tags : CRISPR/Cas9-Based Therapy

Novartis Expands its Cell Therapy Collaboration with Intellia Therapeutics for

Shots: Intellia to receive $10M upfront, milestones and royalties on sales. Novartis to get rights to Intellia’s CRISPR/Cas9 technology for the development of ex-vivo cell therapy using ocular stem cells Under the extension of previous agreement with Novartis, Intellia to get the rights of Novartis’ lipid nanoparticle (LNP) technology for development of genome editing in […]Read More